Biopharmaceutical company Gossamer Bio Inc (Nasdaq:GOSS) reported on Monday the appointment of Richard Aranda, MD as its chief medical officer.

Prior to the promotion, Dr Aranda has served as the senior vice president and head of clinical development in the company, which he joined in February 2018.

Most recently, Dr Aranda was employed as vice president of clinical development at Receptos Inc as well as president of Medical-Science and Inflammation at Novo-Nordisk Inc.

Previously at Bristol Myers Squibb, Dr Aranda was employed as the global medical lead for abatacept (Orencia), as well as early development team lead for early-stage immunology product candidates.

Earlier in his career, Dr Aranda was on the faculty of the Division of Digestive Diseases and West Los Angeles Veterans Affairs, University of California, Los Angeles (UCLA) School of Medicine where he was involved in patient care and laboratory based immunological research.